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Blood samples were collected by a 48-year old male patient with a
diagnosis of disorganized and treatment-resistant Schizophrenia at the
Department of Mental Health of the San Paolo Hospital, Milan (Italy).
The diagnosis of Schizophrenia was conﬁrmed by the assessment of
two independent psychiatrists with the Structured Clinical Interview
for DSM-IV Axis I Disorders (SCID-I). A thorough review of the patient's
history conﬁrmed treatment resistance according to speciﬁc criteria
(Caspi et al., 2004) but also resistance to clozapine, given lack of re-
sponse to the compound and to available pharmacological augmenta-
tion strategies (Sommer et al., 2012).
To generate the SCZ#3-4 iPSC line the four Yamanaka
reprogramming factors OCT4, SOX2, KLF4, and C-MYC (Takahashi et
al., 2007) were delivered into PBMCs using the integration-free Sendai
virus (Fusaki et al., 2009; Yang et al., 2008-2012) gene-deliverymethod
(CytoTune-iPS 2.0 Sendai Reprogramming Kit; Thermo Fischer Scientif-
ic). iPSC-like colonies appeared after 10–12 days and were picked 6–
7 days later (Fig. 1A). One of the clones gave rise to the stable expanding-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Characterization of SCZ#3-4 iPSC line. A: Representative picture of a SCZ#3-4 hiPSC colony (5×) and its karyogram displaying a normal diploid 46, XY karyotype with nomanifest
cytogenetic abnormalities. Immunophenotypical characterization presenting the expression of the pluripotencymarkers OCT4, TRA-1-60, SOX2 (40×). B: RT-PCR showing the expression
of the pluripotency-associated genes in passages 0 and 10 in SCZ#3-4 iPSCs cultures and in another hiPSC clone (#3-14) derived from the same patient. Lack of Sendai virus genome
maintenance is presented in passage 10 cultures. A commercial hiPSC line was used as positive control for pluripotency-associated genes. C: Western Blot analysis showing protein
expression levels of pluripotency-associated markers (NANOG, SOX2, TRA1-60, OCT4) in SCZ#3-4 iPSCs and in other clones derived from the same patient.
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form and speciﬁc OCT4, SOX2 and TRA1-60 immunoreactivity (Fig. 1A).
Expression of pluripotencymarkerswas also conﬁrmed by PCR (Fig. 1B)
and by Western Blot (Fig. 1C) analyses. SCZ#3-4 iPSC line displayed a
normal diploid 46, XY karyotype, without appreciable abnormalities
(Fig. 1B). The absence/presence of Sendai virus genome in cultures at
passage 0 and passage 10 was analyzed by PCR and the loss of the
viral genome was conﬁrmed in passage 10 SCZ#3-4 iPSCs (Fig. 1B).
Pluripotent competence SCZ#3-4 iPSC line was assessed by Embry-
oid Body assay. Cells were cultured for 7 days in EB suspension and for
additional 7 days in adhesion to promote the in vitro maturation to-
wards the three germ layer derivatives (Carpenter et al., 2003). EBs cul-
tures at 14 days displayed the presence of differentiated cells
immunoreactive for ectodermal (β3-Tubulin), mesodermal (α-SMA)
and endodermal (TROMA-1) markers (Fig. 2A). The differentiationFig. 2. In vitro differentiation SCZ#3-4 iPSC line. A: Embryoid Bodies formation assay after 4 da
(β3Tubulin), mesodermal (α-SMA) and endodermal (TROMA-1) germ layermarkers (20×). B:
(ectoderm), Nestin and β3-Tubulin (neuro-ectoderm), T-Brachyury (mesoderm) and AFP (en
reference commercial hiPSCs.competency of SCZ#3-4 iPSCs was comparable to that observed for a
counterpart commercial hiPSC line, as shown by the similar expression
levels of transcripts for FGF5 (ectoderm marker), Nestin (neuro-ecto-
derm marker), T-Brachyury (mesoderm marker), SOX-17 (endoderm
marker) assessed by qRT-PCR (Fig. 2B).Materials and methods
PBMCs collection and freezing
Peripheral Blood Mononuclear Cells (PBMCs) from patients were
isolated in BD Vacutainer CPT Cell Preparation tubes with sodium cit-
rate, after 30 min centrifugation (1800 ×g at room temperature).
PBMCswere collected in PBS for a total volume of 35ml and centrifugedys of suspension culture (5×). D14 cultures exhibit cells immuonoreactive for ectodermal
qRT-PCR showing an analogous expression levels of transcripts for the 3 germ-layers, FGF5
doderm) between 14 days differentiated SCZ#3-4 and SCZ#3-14 iPSCs and differentiated
Table 1
List of primers sequences, amplicons size and number of PCR cycles.
Gene Primer sequence Amplicon size Cycles (PCR)
BETA ACTIN F: GACAGGATGCAGAAGGAGATTACTG R: CTCAGGAGGAGCAATGATCTTGAT 72 bp 25
OCT4 F: GGAAGGAATTGGGAACACAAAGG R: AACTTCACCTTCCCTCCAACCA 71 bp 30
SOX2 F: GCTACAGCATGATGCAGGACCA R: TCTGCGAGCTGGTCATGGAGTT 135 bp 30
c-myc F: CCTGGTGCTCCATGAGGAGAC R: CAGACTCTGACCTTTTGCCAGG 128 bp 30
KLF4 F: CATCTCAAGGCACACCTGCGAA R: TCGGTCGCATTTTTGGCACTGG 156 bp 30
NANOG F: CCTGTGATTTGTGGGCCTG R: GACAGTCTCCGTGTGAGGCAT 78 bp 30
SEV F: GGATCACTAGGTGATATCGAGC R: ACCAGACAAGAGTTTAAGAGATATGTATC 181 bp 35
Nestin F: GGAGAAGGACCAAGAACTG R: ACCTCCTCTGTGGCATTC 153 bp qRT-PCR
T-Brachyury F: CCTTCAGCAAAGTCAAGCTCACC R: TGAACTGGGTCTCAGGGAAGCA 153 bp qRT-PCR
FGF5 F: GGAATACGAGGAGTTTTCAGCAAC R: CTCCCTGAACTTGCAGTCATCTG 99 bp qRT-PCR
AFP F: GCAGAGGAGATGTGCTGGATTG R: CGTGGTCAGTTTGCAGCATTCTG 113 bp qRT-PCR
β3-Tubulin F: TCAGCGTCTACTACAACGAGGC R: GCCTGAAGAGATGTCCAAAGGC 120 bp qRT-PCR
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with 10% DMSO. 2 × 106 cells were aliquoted and frozen.
PBMCs thawing and reprogramming with Sendai virus particles
PBMCswere thawed at 37 °C and centrifuged at 200×g for 10min in
expansion medium (EM) made of StemPro-34 Serum Free Medium
(SFM, Thermo Fisher Scientiﬁc) Basal Medium, StemPro-34 Nutrient
Supplement, 200 mM GlutaMAX, 1% Penicillin/Streptomycin,
100 ng/ml Stem Cell Factor (SCF, Prepotech), 100 ng/ml FLT-3 (Thermo
Fisher Scientiﬁc), 20 ng/ml Interleukin-6 (IL-6) (Thermo Fisher Scientif-
ic), 20 ng/ml Interleukin-3 (IL-3) (Thermo Fisher Scientiﬁc). The medi-
um was replaced daily for the following 3 days.
In order to deliver reprogramming genes in PBMCs, viral particles
provided with the CytoTune-iPS 2.0 Sendai Reprogramming Kit (Ther-
mo Fisher Scientiﬁc) were used following the manufacturer's protocol.
20 days post-transduction colonies with iPSCs morphology appeared
and were picked, transferred onto a new well and cultured on
Geltrex-coated plastic dish in E8 medium according to the
manufacture's protocol.
In vitro differentiation
Embryoid Bodies (EB) formation assay was performed by gently
resuspending iPSCs clumps in 100-mm non-tissue culture-treated dish
in Essential 6 medium (E6 medium; Thermo Fisher Scientiﬁc). Medium
was changed daily. At day 7, EBs were collected and plated on Geltrex-
coated dishes in E6 medium to allow growth in adhesion for further
7 days. Medium was changed every other day.Table 2
List of the antibodies used in for immunocytochemistry (IC) and Western Blot (WB) assays, w
Antibody Company
TRA1-60 Santa Cruz Biotech
NANOG Santa Cruz Biotech
SOX2 Millipore
OCT4 (WB) Santa Cruz Biotech
LAMIN A/C Santa Cruz Biotech
OCT4 (IC) Santa Cruz Biotech
α-SMA Sigma
TROMA-1 Iowa DHB
AFP Abnova
β3-Tubulin Promega
Anti-rabbit HRP BioRad
Anti-mouse HRP BioRad
Anti-mouse IgM FITC Santa Cruz Biotech
Alexa Fluor IgG anti-rabbit 568 Life Technologies
Alexa Fluor IgG anti-rabbit 488 Life Technologies
Anti-mouse IgM FITC Santa Cruz Biotech
Alexa Fluor IgG anti-mouse 568 Life TechnologiesRNA isolation, polymerase chain reaction (PCR) and quantitative-PCR
(qPCR)
RNAwas isolatedwith the TRIzol Reagent (Thermo Fisher Scientiﬁc)
following the manufacture's protocol and reverse transcribed using
iScript cDNA Synthesis Kit (BioRad). Transcripts of interest were ampli-
ﬁed using EURO TAQ Thermostable DNA polymerase (EUROCLONE) and
detection of genes of interestwas conﬁrmedwith speciﬁc primes (Table
1). Quantitative Reverse Transcription-Polymerase Chain Reaction
(qRT-PCR) was performed using the SsoAdvanced Universal SYBR
Green Supermix Kit following the manufacturer's instructions. Beta-
actin was used as housekeeping gene to normalize data. Ampliﬁcation
was performed on a CFX96 BioRad machine. Results were analyzed
with BioRad CFX Manager dedicated software.
Immunoﬂuorescence assay
Cells were ﬁxed with PFA 4% for 15 min RT, permeabilized with Tri-
ton 0.5% for 15minutes RT and blockedwith blocking solution (10% FBS
in PBS) for 1 h at RT. Cultureswere then incubatedwith speciﬁc primary
antibodies overnight at 4 °C (Table 2) and stained for 45min at RT with
secondary antibody and Hoechst 33258 1 μg/ml (Thermo Fischer Scien-
tiﬁc). Images were detected with the microscope Leica DM IL Led Fluo
with Leica DFC450 C camera (Leica Microsystem).
Western Blot assay
Cultures were lysed in SDS Sample Buffer (62.5 mM Tris-HCl ph 6.8;
2% SDS; 10% Glycerol; 50 mM DTT; Bromophenol Blue). Samples wereorking dilution and species in which they are produced.
Dilution Species
1:1000 (WB) 1:200 (IC) Mouse IgM
1:1000 Mouse
1:2000 (WB) 1:300 (IC) Rabbit
1:1000 Mouse
1:1000 Rabbit
1:100 Rabbit
1:100 Mouse
1:100 Mouse
1:50 Rabbit
1:1000 Mouse
1:3000 Goat
1:3000 Goat
1:200 Goat
1:300 Goat
1:300 Goat
1:200 Goat
1:400 Donkey
664 F. Marsoner et al. / Stem Cell Research 17 (2016) 661–664boiled at 95 °C for 5 min and loaded in the 8% polyacrylamide gel and
proteins blotted on a PVDFmembrane bymeans of Trans Blot Turbo ap-
paratus (BioRad). Primary antibodies (Table 2) were incubated over-
night at 4 °C in agitation and secondary antibody for 45 min at RT.
Signal was detected with the ECL Clarity system (BioRad) in dark cham-
berUVITECHCambridge (Uvitech) andUvitech softwarewas used to ac-
quire and analyze the data.Karyotyping
Cell cultures were treated with colcemid (Gibco KaryoMAX
Colcemid solution in PBS, ThermoFischer Scientiﬁc) at aﬁnal concentra-
tion of 10 ng/ml for 16 h (overnight) at 37 °C and metaphases harvest
was carried out according to standard protocols. Brieﬂy, PBS washed
cells were treated with hypotonic solution (0.075 M KCl for 15 min at
RT) and ﬁxed in acetic acid/methanol (1:3 v/v). Air-dried metaphase
spreads slideswere analyzed byQFQ banding following standard proce-
dures. Microscope observationwas performed using a Nikon Eclipse 90i
(Nikon Instruments, Japan) equipped with the acquisition and analysis
Genikon software (Nikon Instruments S.p.a. Italy).Acknowledgements
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